Di Long (Pheretima)'s anticancer pharmacodynamics

[Guest guest]

On 1/2/07, Bob Flaws <pemachophel2001 wrote:

>

> The anticancer pharmacodynamics of Di Long are categorized

> under five heads:

>

> 1. Controls tumor growth

> 2. Promotes cell aptosis

> 3. Strengthens immunity

> 4. Combats oxidation

> 5. Improves blood hypercoagulability

>

 

 

 

 

 

 

 

 

 

 

Does anybody know what #5 is saying? Does that " thicken " or " thin " the

blood?

 

 

--

 

Pain is inevitable, suffering is optional.

 

 

 

[Guest guest]

Thins

 

, " Al Stone " <al wrote:

>

> On 1/2/07, Bob Flaws <pemachophel2001 wrote:

> >

> > The anticancer pharmacodynamics of Di Long are categorized

> > under five heads:

> >

> > 1. Controls tumor growth

> > 2. Promotes cell aptosis

> > 3. Strengthens immunity

> > 4. Combats oxidation

> > 5. Improves blood hypercoagulability

> >

>

>

>

>

Does anybody know what #5 is saying? Does that " thicken " or " thin " the

> blood?

>

>

> --

>

> Pain is inevitable, suffering is optional.

>

>

>

[Guest guest]

Hi Al,

 

Hypercoagulability refers to the coagulation of blood more rapidly than

normal. I would take #5 (Improving blood hypercoagulability) to mean that di

long is decreasing the tendency for blood to clot more rapidly than normal)

 

Hematological effets of oral or intracenous injection of di long inhibits the

formation of thrombi and facilitates their dissolution. Zhe Jian Zhong Yi Za Zhi

(Ahejiang Jounal of ), 1991: 26(11):512 (from Chinese Medical

Herbology and Pharmacology by John K. Chen)

 

I'm not exactly sure what this has to do with cancer because some tumor cells

actually produce chemical messengers that stimulate angiogenesis (the growth of

new blood vessels) this increases the blood supply to the cancer cells.

Hypercoagulability is not something that I would associate with cancer (perhaps

come blood disorder), it would seem counter intuitive.

 

Many western anti-cancer therapies (chemotherapy or radiation) may decrease

platlet levels resulting in decreased clotting time. However it doesn't

necessarily follow that decreasing clotting time is going to be an effective

anti-cancer treatment. The decreased clotting time is more a side affect.

 

Just some thoughts,

Steve

 

Al Stone <al wrote:

On 1/2/07, Bob Flaws <pemachophel2001 wrote:

>

> The anticancer pharmacodynamics of Di Long are categorized

> under five heads:

>

> 1. Controls tumor growth

> 2. Promotes cell aptosis

> 3. Strengthens immunity

> 4. Combats oxidation

> 5. Improves blood hypercoagulability

>

 

Does anybody know what #5 is saying? Does that " thicken " or " thin " the

blood?

 

--

 

Pain is inevitable, suffering is optional.